Overview
Low Dose Atropine for Symptomatic Vitreous Floaters
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-06-01
2024-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The objective of this study is to identify a potential pharmacologic option by assessing whether 0.01% atropine may be effective for treating bothersome floaters as measured by scores on a modified NEI VFQ-25.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Jeanette DuTreatments:
Atropine
Ophthalmic Solutions
Criteria
Inclusion Criteria:- Adult patients within Prism Vision Group with ICD diagnosis of acute posterior
vitreous detachment and none of the ocular comorbidities listed as exclusion criteria
will be screened as potential study participants.
Exclusion Criteria:
- Patients with vitreous hemorrhage, other significant media opacity or vitreoretinal
pathology, or history of pars plana vitrectomy will be excluded.